Pegylated human interferon alpha 2a does not induce depression-associated changes in mice

Psychiatry Research

Volumn 185, Issue 1-2, 2011, Pages 243-247

  Kosel, Markus ^a,e   Bilkei Gorzo, Andras ^b   Zawatzky, Rainer ^c   Zimmer, Andreas ^b   Schlaepfer, Thomas E ^a,d  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d JOHNS HOPKINS HOSPITAL   (United States)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Anhedonia; Dexamethasone suppression test; Forced swim test; Pharmacokinetics

Indexed keywords

PEGINTERFERON ALPHA2A;

ANHEDONIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DEXAMETHASONE SUPPRESSION TEST; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; FORCED SWIMMING TEST; HEPATITIS C; HOPELESSNESS; HUMAN; HUMAN CELL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TOXICITY TESTING;

ANIMALS; ANTIVIRAL AGENTS; DEPRESSION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERFERON ALFA-2A; MALE; MICE; POLYETHYLENE GLYCOLS; TIME FACTORS;

EID: 78650200750     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2009.10.012     Document Type: Article

References (25)

1. Asnis G.M., De La Garza R. Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches. Journal of Clinical Gastroenterology 2006, 40:322-335.
2. Bailon P., Palleroni A., Schaffer C.A., Spence C.L., Fung W.J., Porter J.E., Ehrlich G.K., Pan W., Xu Z.X., Modi M.W., Farid A., Berthold W., Graves M. Rational design of a potent, long-lasting form of interferon: a 40kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjugate Chemistry 2001, 12:195-202.
3. Capuron L., Miller A.H. Cytokines and psychopathology: lessons from interferon-alpha. Biological Psychiatry 2004, 56:819-824.
4. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Analytical Biochemistry 1987, 162:156-159.
5. Crnic L.S., Segall M.A. Behavioral effects of mouse interferons-alpha and -gamma and human interferon-alpha in mice. Brain Research 1992, 590:277-284.
6. Cryan J.F., Markou A., Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends in Pharmacological Sciences 2002, 23:238-245.
7. De La Garza R., Asnis G.M., Pedrosa E., Stearns C., Migdal A.L., Reinus J.F., Paladugu R., Vemulapalli S. Recombinant human interferon-alpha does not alter reward behavior, or neuroimmune and neuroendocrine activation in rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2005, 29:781-792.
8. Deutsch M., Hadziyannis S.J. Old and emerging therapies in chronic hepatitis C: an update. Journal of Viral Hepatitis 2008, 15:2-11.
9. Dunn A.L., Crnic L.S. Repeated injections of interferon-alpha A/D in Balb/c mice: behavioral effects. Brain, Behavior, and Immunity 1993, 7:104-111.
10. Feinberg A.P., Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Analytical Biochemistry 1983, 132:6-13.
11. Loftis J.M., Wall J.M., Pagel R.L., Hauser P. Administration of pegylated interferon-alpha-2a or -2b does not induce sickness behavior in Lewis rats. Psychoneuroendocrinology 2006, 31:1289-1294.
12. Makino M., Kitano Y., Hirohashi M., Takasuna K. Enhancement of immobility in mouse forced swimming test by treatment with human interferon. European Journal of Pharmacology 1998, 356:1-7.
13. Makino M., Kitano Y., Komiyama C., Hirohashi M., Kohno M., Moriyama M., Takasuna K. Human interferon-alpha induces immobility in the mouse forced swimming test: involvement of the opioid system. Brain Research 2000, 852:482-484.
14. Makino M., Kitano Y., Komiyama C., Hirohashi M., Takasuna K. Involvement of central opioid systems in human interferon-alpha induced immobility in the mouse forced swimming test. British Journal of Pharmacology 2000, 130:1269-1274.
15. Nickolaus P., Rammensee H.G., Zawatzky R. Molecular cloning of a macrophage-derived, interferon-inducible secreted immunoglobulin-binding protein. European Journal of Immunology 1999, 29:1504-1512.
16. Pestka S., Krause C.D., Walter M.R. Interferons, interferon-like cytokines, and their receptors. Immunological Reviews 2004, 202:8-32.
17. Porsolt R.D. Animal models of depression: utility for transgenic research. Reviews in the Neurosciences 2000, 11:53-58.
18. Porsolt R.D., Le Pichon M., Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732.
19. Raison C.L., Demetrashvili M., Capuron L., Miller A.H. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 2005, 19:105-123.
20. Raison C.L., Capuron L., Miller A.H. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends in Immunology 2006, 27:24-31.
21. Schiepers O.J., Wichers M.C., Maes M. Cytokines and major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2005, 29:201-217.
22. Segall M.A., Crnic L.S. An animal model for the behavioral effects of interferon. Behavioral Neuroscience 1990, 104:612-618.
23. Shuto H., Kataok A.Y., Horikawa T., Fujihara N., Oishi R. Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain. Brain Research 1997, 747:348-351.
24. Wang J., Campbell I.L., Zhang H. Systemic interferon-alpha regulates interferon-stimulated genes in the central nervous system. Molecular Psychiatry 2008, 13:293-301.
25. World Medical Association World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. Journal of Postgraduate Medicine 2002, 48:206-208.